drugtargetreview.com
Repurposed cancer drugs target root cause of Crohn's Disease
This work targets a possible root cause (epithelial stress and cell death) rather than only suppressing inflammation — if validated in humans, it could offer new treatment options for people who don’t respond to current therapies.
Because the drugs are already FDA-approved for other uses, clinical testing might move faster than for a brand-new drug.
Adult patients with Crohn’s disease, clinicians treating IBD, and researchers working on epithelial biology, drug repurposing, or IBD therapeutics.
What To Know
Researchers at the University of Houston report preclinical work repurposing two cancer drugs (pazopanib and ponatinib) to block a chronic cellular stress signal in intestinal epithelial cells that leads to necroptosis and impaired gut barrier repair in Crohn’s disease models.
The team suggests low doses of these approved cancer drugs reduced epithelial cell death and allowed the lining to regenerate, which could break the cycle of barrier failure driving inflammation. This article summarizes discovery-stage research and frames repurposing as a faster path to patients because the drugs are already FDA-approved for cancer.
It does not present clinical trial data or patient outcomes in Crohn’s disease, nor does it specify study design, models used, or safety in this indication. If you want to read the original research, look for the University of Houston team and authors like Seema Khurana for the primary study details and any announced clinical plans.
The report is based on preclinical/basic research and media coverage; it does not describe completed clinical trials in Crohn’s disease. Pazopanib and ponatinib have established safety profiles in cancer but may have different risks at the doses and in the patient population considered here. Further clinical testing is required before any treatment changes.
